Lipid Screening Intervals Based on Age and Risk
Screen all adults starting at age 19 years with lipid profiles at least every 5 years, with more frequent testing based on age and cardiovascular risk factors: young adults (20-45 years for men, 20-55 years for women) every 5 years; middle-aged adults (45-65 years for men, 55-65 years for women) every 1-2 years without risk factors or more frequently with multiple risk factors; and older adults (>65 years) annually regardless of sex. 1
Age-Stratified Screening Recommendations
Young Adults (Ages 20-45 for Men, 20-55 for Women)
- Baseline screening at age 19 years with repeat testing every 5 years for those without additional ASCVD risk factors 1, 2
- This interval applies to individuals with low cardiovascular risk profiles
- More frequent testing is warranted when multiple global ASCVD risk factors emerge 1
Middle-Aged Adults (Ages 45-65 for Men, 55-65 for Women)
- Screen at least every 1-2 years in the absence of ASCVD risk factors 1
- More frequent testing (potentially annually) is recommended when multiple global ASCVD risk factors are present 1
- The frequency should be based on individual clinical circumstances and clinician judgment 1
- This represents the highest-quality recommendation (Grade A; BEL 1) in the AACE/ACE guidelines 1
Older Adults (>65 Years)
- Annual screening for those with 0-1 ASCVD risk factors 1
- Annual or more frequent screening for those with multiple ASCVD global risk factors 1
- Screening recommendations are identical for both men and women in this age group 1
- This age-based approach reflects the Grade A evidence supporting annual assessment 1
Special Populations Requiring Modified Intervals
Children and Adolescents
- Universal screening at ages 9-11 years to identify familial hypercholesterolemia and other significant lipid disorders 2, 3
- Repeat screening at ages 17-21 years 3
- For children at risk for FH (family history of premature CVD or elevated cholesterol): screen at age 3 years, again between ages 9-11, and again at age 18 1
- Children as young as age 2 years should be screened if there is family history of early CVD or severe hypercholesterolemia 3
Patients with Diabetes
- Annual testing for adults with diabetes, or more frequently if needed to achieve lipid goals 4
- In adults with low-risk lipid values (LDL <100 mg/dL, HDL >60 mg/dL, triglycerides <150 mg/dL), repeat assessments every 2 years 4
Patients on Lipid-Lowering Therapy
While the guidelines focus primarily on screening intervals for untreated individuals, those already on therapy require monitoring based on treatment response and clinical circumstances 1
Key Clinical Considerations
Risk factor assessment drives frequency: The presence of multiple ASCVD risk factors—including hypertension, diabetes, smoking, family history of premature ASCVD, obesity, or metabolic syndrome—should prompt more frequent testing than the baseline intervals 1
Fasting vs. nonfasting: Use a fasting lipid profile for the most precise assessment, including total cholesterol, LDL-C, triglycerides, HDL-C, and non-HDL-C 1. However, lipids can be measured in the non-fasting state if fasting is impractical 1
Common pitfall: The 2017 AACE/ACE guidelines provide the most granular age- and risk-stratified recommendations, with Grade A evidence supporting annual screening in older adults and every 1-2 years in middle-aged adults 1. The 2026 ACC/AHA guidelines align with screening starting at age 19 and at least every 5 years thereafter, with more frequent screening for those with additional risk factors 2. These recommendations are more aggressive than older approaches that suggested screening only every 5 years across all adult age groups 5.
ESC/EAS approach: European guidelines recommend screening men >40 years and women >50 years or postmenopausal 6, which differs slightly from the American approach of universal adult screening starting at age 19-20 years.
The evidence consistently supports that screening frequency should escalate with age and accumulating risk factors, reflecting the cumulative lifetime exposure to atherogenic lipoproteins as the principal driver of ASCVD risk 7, 8.